-
Bextra Will Not Return In Canada As Safety Risks Outweigh Benefits
Health Canada Safety Panel Cites Heart Attacks, Strokes, and Severe Skin Reactions Bextra, Pfizer’s anti-inflammatory drug for arthritis patients, will not be returned to the Canadian market according to a Health Canada announcement in…
-
FDA’s David Graham Says U.S. Drug Safety System No Better in 2005
Graham Criticizes Agency’s Performance During The Year Since Vioxx Recall In November 2004 David Graham, associate director for science and medicine at the FDA’s Office of Drug Safety, criticized the FDA’s drug oversight practices…
-
Large Study to Investigate Heart Risks Of Celebrex, Ibuprofen, and Naproxen
Cleveland Clinic’s Dr. Nissen To Lead 20,000 Patient "Precision" Clinical Trial In mid-December 2005 the drug company Pfizer Inc. announced that Dr. Steven E. Nissen, medical director of the Cleveland Clinic’s cardiovascular coordinating center,…
-
December 2005 FDA “Patient Safety News” Videos For Doctors Online
Edition Covers Paxil, Strattera, Menactra Meningococcal Vaccine, and More The FDA’s Patient Safety News (PSN) is a series of monthly video news shows intended primarily for doctors and other health care professionals. Generally, this…
-
Judge Fallon Declares Mistrial In Irvin / Plunkett Vioxx Case
Merck’s Vioxx Trial Record to Date: One Victory, One Loss, One Draw The Reuters news service reported at 10:00 a.m. EST Monday, December 12, 2005 that Judge Eldon Fallon declared a mistrial in Irvin…
-
Irvin / Plunkett Vioxx Case Awaits A Verdict As Texas Jury Deliberates
Merck’s Attorney Phil Beck Put On Just Four Defense Witnesses In Vioxx Trial On December 8, 2005 the plaintiff and defense lawyers in the third Vioxx trial, Irvin / Plunkett v. Merck & Co.,…
